BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29023927)

  • 21. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
    Mira JA; Neukam K; López-Cortés LF; Rivero-Juárez A; Téllez F; Girón-González JA; de los Santos-Gil I; Ojeda-Burgos G; Merino D; Ríos-Villegas MJ; Collado A; Torres-Cornejo A; Macías J; Rivero A; Pérez-Pérez M; Pineda JA; ;
    Eur J Clin Microbiol Infect Dis; 2015 Sep; 34(9):1879-84. PubMed ID: 26115631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
    Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
    Andersen ES; Moessner BK; Christensen PB; Kjær M; Krarup H; Lillevang S; Weis N
    Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):41-4. PubMed ID: 21079513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
    D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
    J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Helicobacter pylori seropositivity: influence on severity and treatment response in patients with chronic hepatitis C.
    Umemura T; Muto H; Tanaka E; Matsumoto A; Ichijo T; Yoshizawa K; Akamatsu T; Kiyosawa K;
    J Viral Hepat; 2007 Jan; 14(1):48-54. PubMed ID: 17212644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
    van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C.
    Squadrito G; Cacciola I; Alibrandi A; Pollicino T; Raimondo G
    J Hepatol; 2013 Oct; 59(4):696-700. PubMed ID: 23751755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
    Lin KH; Hsu PI; Yu HC; Lin CK; Tsai WL; Chen WC; Chan HH; Lai KH
    BMC Gastroenterol; 2012 Jan; 12():7. PubMed ID: 22257364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
    Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ;
    Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
    Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
    J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals.
    Seko Y; Moriguchi M; Takahashi A; Okishio S; Kataoka S; Okuda K; Mizuno N; Takemura M; Taketani H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
    Intern Med; 2020; 59(15):1811-1817. PubMed ID: 32741890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection.
    Wang CS; Yao WJ; Wang ST; Chang TT; Chou P
    Clin Infect Dis; 2004 Sep; 39(6):790-6. PubMed ID: 15472809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematologic indices improve with eradication of HCV in patients with cirrhosis and predict decompensation.
    Karagozian R; Grace ND; Qamar AA
    Acta Gastroenterol Belg; 2014 Dec; 77(4):425-32. PubMed ID: 25682633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.
    ANRS CO13 HEPAVIH Cohort
    AIDS; 2015 Sep; 29(14):1821-30. PubMed ID: 26372388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Helicobacter pylori eradication on refractory thrombocytopenia in patients with chronic HCV awaiting antiviral therapy.
    Hanafy AS; El Hawary AT; Hamed EF; Hassaneen AM
    Eur J Clin Microbiol Infect Dis; 2016 Jul; 35(7):1171-6. PubMed ID: 27180243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.